XBIT logo

XBiotech Inc

XBIT

XBIT: XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.

more

Show XBIT Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of XBIT by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard
Insider Trading

Quarterly net insider trading by XBIT's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Compositions and methods for treating and preventing Jun. 28, 2022
  • Patent Title: Compositions and methods for treating and preventing Mar. 03, 2020
  • Patent Title: Treatment for neoplastic diseases May. 21, 2019
  • Patent Title: Compositions and methods for treating and preventing Feb. 26, 2019
  • Patent Title: Cachexia treatment Feb. 12, 2019
  • Patent Title: Treatment of diabetes Jun. 05, 2018
  • Patent Title: Treatment of dermatological pathologies Feb. 27, 2018
  • Patent Title: Human antibody specific for interleukin-1alpha Dec. 12, 2017
  • Patent Title: Cachexia treatment Nov. 07, 2017
  • Patent Title: Compositions and methods for treating and preventing Oct. 10, 2017
  • Patent Title: Treatment of inflammatory skin disease Aug. 08, 2017
  • Patent Title: Immunoglobulin variable region libraries Jun. 06, 2017
  • Patent Title: Treatment of diabetes Jan. 17, 2017
  • Patent Title: Compositions and methods for treating and preventing Nov. 08, 2016
  • Patent Title: Identifying affinity-matured human antibodies Sep. 27, 2016
  • Patent Title: Compositions and methods for treating and preventing Aug. 16, 2016
  • Patent Title: Identifying affinity-matured human antibodies Jul. 19, 2016
  • Patent Title: Identifying affinity-matured human antibodies Jan. 12, 2016
  • Patent Title: Human antibody specific for il-1alpha Nov. 10, 2015
  • Patent Title: Interleukin-1α antibodies and methods of use Feb. 24, 2015
  • Patent Title: Nucleic acids encoding a human monoclonal antibody that specifically binds to il-1α Feb. 17, 2015
  • Patent Title: Increasing anti-il-1α antibodies in a subject Oct. 21, 2014
  • Patent Title: Method for killing il-1 alpha expressing cells Jul. 22, 2014
  • Patent Title: Inhibiting cell migration Mar. 25, 2014
  • Patent Title: Modulation of pathogenic cd14+/cd16+ monocytes Oct. 01, 2013
  • Patent Title: Interleukin-1 alpha antibodies and methods of use Mar. 05, 2013
  • Patent Title: Interleukin-1 alpha antibodies and methods of use Mar. 05, 2013
  • Patent Title: Modulation of the amount or function of pathogenic cd14+cd16+ monocytes Aug. 14, 2012
  • Patent Title: Diagnosis, treatment, and prevention of vascular disorders using il-1 autoantibodies May. 29, 2012
  • Patent Title: Interleukin-1α antibodies Oct. 11, 2011
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of XBIT in WallStreetBets Daily Discussion

XBIT News

Recent insights relating to XBIT

CNBC Recommendations

Recent picks made for XBIT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in XBIT

Corporate Flights

Flights by private jets registered to XBIT